Rhythm Pharmaceuticals Inc (RYTM) Shares Sold by D. E. Shaw & Co. Inc.

Share on StockTwits

D. E. Shaw & Co. Inc. trimmed its position in shares of Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) by 78.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,982 shares of the company’s stock after selling 41,179 shares during the period. D. E. Shaw & Co. Inc.’s holdings in Rhythm Pharmaceuticals were worth $295,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in RYTM. Federated Investors Inc. PA increased its holdings in shares of Rhythm Pharmaceuticals by 216.2% during the 3rd quarter. Federated Investors Inc. PA now owns 790,421 shares of the company’s stock worth $23,057,000 after buying an additional 540,421 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Rhythm Pharmaceuticals by 36.2% during the 4th quarter. BlackRock Inc. now owns 1,554,706 shares of the company’s stock worth $41,790,000 after buying an additional 413,203 shares during the last quarter. Vanguard Group Inc increased its holdings in shares of Rhythm Pharmaceuticals by 12.3% during the 3rd quarter. Vanguard Group Inc now owns 1,048,186 shares of the company’s stock worth $30,575,000 after buying an additional 115,177 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Rhythm Pharmaceuticals by 12.3% during the 3rd quarter. Vanguard Group Inc. now owns 1,048,186 shares of the company’s stock worth $30,575,000 after buying an additional 115,177 shares during the last quarter. Finally, Emory University acquired a new stake in shares of Rhythm Pharmaceuticals during the 4th quarter worth $2,225,000. Institutional investors and hedge funds own 92.00% of the company’s stock.

Shares of Rhythm Pharmaceuticals stock opened at $25.74 on Tuesday. Rhythm Pharmaceuticals Inc has a twelve month low of $21.44 and a twelve month high of $37.23. The firm has a market cap of $912.57 million, a P/E ratio of -10.77 and a beta of 1.40.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings results on Friday, March 8th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.17). As a group, analysts anticipate that Rhythm Pharmaceuticals Inc will post -3.01 earnings per share for the current year.

In related news, CEO Keith Michael Gottesdiener sold 15,779 shares of the company’s stock in a transaction on Wednesday, January 23rd. The shares were sold at an average price of $30.05, for a total transaction of $474,158.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have sold 65,637 shares of company stock valued at $1,971,840. 4.93% of the stock is owned by corporate insiders.

RYTM has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Rhythm Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, February 21st. BidaskClub upgraded Rhythm Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, February 13th. Stifel Nicolaus set a $34.00 price objective on Rhythm Pharmaceuticals and gave the stock a “hold” rating in a report on Thursday, March 28th. LADENBURG THALM/SH SH initiated coverage on Rhythm Pharmaceuticals in a report on Wednesday, March 13th. They set a “buy” rating and a $43.00 price objective for the company. Finally, ValuEngine upgraded Rhythm Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, March 15th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $39.00.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/4296067/rhythm-pharmaceuticals-inc-rytm-shares-sold-by-d-e-shaw-co-inc.html.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders.

Recommended Story: What is Net Asset Value (NAV)?

Want to see what other hedge funds are holding RYTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rhythm Pharmaceuticals Inc (NASDAQ:RYTM).

Institutional Ownership by Quarter for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Morpheus.Network  24 Hour Volume Tops $164,044.00
Morpheus.Network 24 Hour Volume Tops $164,044.00
Soarcoin  Hits Market Cap of $1.73 Million
Soarcoin Hits Market Cap of $1.73 Million
Interstellar Holdings  Hits Market Cap of $1.74 Million
Interstellar Holdings Hits Market Cap of $1.74 Million
Brokerages Expect Aquabounty Technologies Inc  Will Announce Quarterly Sales of $250,000.00
Brokerages Expect Aquabounty Technologies Inc Will Announce Quarterly Sales of $250,000.00
Neblio 24 Hour Trading Volume Tops $843,624.00
Neblio 24 Hour Trading Volume Tops $843,624.00
Maker  Market Cap Reaches $680.31 Million
Maker Market Cap Reaches $680.31 Million


© 2006-2019 Ticker Report